JMCC Group boosts European presence with acquisition of EU GMP certified cannabis production facility in Malta
May 16, 2023 By Grow Opportunity Staff
Toronto — Toronto-headquartered JMCC Group has acquired Materia Malta’s world–class, EU-GMP certified medical cannabis production facility as well as all other assets of Materia’s Maltese operations. The Malta operations will be renamed JMCC Life Sciences, Europe.
Materia Malta’s 32,000–square–foot processing and manufacturing facility is ideally suited to dovetail with JMCC’s other pharma-level infrastructure including the company’s 135,000-square-foot GACP cultivation site and its 20,000-square-foot processing centre, both in Jamaica. It will also complement its GDP warehousing and distribution facility, JMCC European Distribution Ltd, located between England and France on the Channel Island of Jersey.
The acquisition accelerates JMCC’s operations in Europe and the United Kingdom, and positions JMCC to better support patients throughout the region. It also reinforces the Group’s ability to align with market demand for JMCC’s naturally grown, medical-grade dried flower and its unique nano-emulsified formulations.
Diane Scott, JMCC Group chair & CEO said that the addition of the Malta operation is consistent with the company’s strategic commitment to focus 100 per cent on the medical market. In 2018, the country enacted the Production of Cannabis for Medicinal and Research Purposes Act to provide the legal framework for production, following the amendment of Malta’s Drug Dependence Act to allow prescriptions for medicinal preparations of cannabis. The country introduced a legal regime for adult use of cannabis in 2022. But, as in other countries where adult/recreational use has been legalized, JMCC will stick to the medical side only.
“We’ve made a commitment to both patients and healthcare professionals globally that JMCC will invest in the R&D required to produce science-led and pharma-like products that are scientifically proven to be safe and effective as well as easier for patients and prescribers to use.And we’re sticking with that promise, despite the bigger financial appeal the rec market might offer.” — Diane Scott, CEO, JMCC Group
Print this page